THE US FDA has approved
Brisdelle (paroxetine) to treat
moderate-to-severe vasomotor
symptoms (hot flashes) associated
with menopause.
It’s the first non-hormonal
drug approved in the US for this
indication, and because it contains
the same active ingredient as
medicines for depression its label
will have a warning about suicidal
thoughts.The above article was sent to subscribers in Pharmacy Daily's issue from 02 Jul 13 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 02 Jul 13
MONTU Group, its subsidiary Alternaleaf Pty Ltd, and their common director Christopher Strauch are facing legal action by the Therapeutic Goods Administration (TGA) in the Federal Court of Australia for alleged unlawful advertising on the effectiveness of their medicinal cannabis products.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.